Pharmacies Would Notify Patients of Substitutions

Summary#

A-5784, titled “Requires pharmacist or pharmacist's designee to notify consumer of substituted drug or biological product,” would amend New Jersey’s 1977 drug-substitution law and 2015 biological-product law; it would not create a separate program. Its stated goal is to notify consumers when a pharmacist substitutes a product. The bill is introduced and is not law. The parent Acts were not supplied, so their current wording could not be independently checked.

  • For a drug substitution, the pharmacist or the pharmacist’s agent would have to notify the consumer when the substituted drug is dispensed.
  • For a biological-product substitution, the pharmacist or designee would have to notify the patient at the time it is dispensed.
  • The bill leaves the stated substitution conditions in place: drug substitutions must meet the existing lower-cost and interchangeable-list conditions shown in the bill text; biological substitutions require that the prescriber did not bar substitution and that the FDA has found the product interchangeable or therapeutically equivalent.
  • For biological products, the bill also keeps the requirements to record the product and manufacturer on the prescription label and dispensing record, and to communicate the product information to the prescriber, subject to existing exceptions.

What it means for you#

  • Consumers: If a pharmacist dispenses a substituted drug or biological product, the pharmacist or a designee would have to notify you at the time it is dispensed. For drug substitutions, the supplied text retains the option to ask about price savings before filling a prescription and, if dissatisfied with the savings, to request the prescribed product.
  • Pharmacists and pharmacy staff: They would have a new notice duty for consumers. For biological products, the duty falls on the pharmacist or designee; for other drugs, it falls on the pharmacist or agent.
  • Prescribers: The bill does not remove the existing biological-product communication to prescribers described in its text. That communication is generally due within five business days, with exceptions for certain unchanged refills and when no qualifying substitute exists.
  • What does not change in the bill text: It does not require a substitution when the stated conditions are not met, or change the stated right to prevent substitution. It does not create a new consumer benefit or change drug prices directly.

Money#

No publicly available information on the bill’s cost.

  • The bill requires notification but gives no estimate of pharmacy costs, staffing needs, or public spending.
  • The supplied text does not create a fee, fine, tax, or appropriation.

What is unclear#

  • The bill does not say how notice must be given or what information it must include.
  • It does not explain how notice works when the product is not handed to the consumer in person.
  • The bill does not define “consumer” or set rules for who may receive notice on the consumer’s behalf.
  • The parent Acts were not supplied, so the available material does not allow a full check of how these changes compare with current law.

Case for#

  • A possible argument for the bill is that consumers should be told when the product they receive differs from the one prescribed.
  • Notice at the time of dispensing could give consumers timely information about the product provided.
  • The biological-product provisions also require the product and manufacturer to be recorded and communicated to the prescriber, which may support clear records of what was dispensed.

Case against#

  • The bill does not specify how notice must be delivered or what it must say, leaving those practical details open.
  • It creates a new duty for pharmacies but gives no cost estimate or details about staffing or implementation.
  • The bill sets no process for checking whether consumers actually receive or understand the notice.